Mahmut Onur KARAYTUĞ, Mehmet Emin DEMİRKOL, Lut TAMAM

Selektif serotonin geri alım inhibitörünün neden olduğu ve agomelatin ile düzelen akut açı kapanması glokomu

ir MT1 ve MT2 reseptör agonisti ve 5-HT2C antagonisti olan agomelatin, majör depresif bozukluk tedavisinde kullanılan bir antidepresandır. Melatoninin ve analoglarının göz içi basıncı düşürücü etkisi birkaç deneysel çalışmada gösterilmiştir. Bu olgu sunumunda, oral agomelatin tedavisi ile düzelen açı kapanması glokomu aynı anda selektif serotonin geri alım inhibitörü alan majör depresif bozukluk tanılı bir hastada anlatılmaktadır. Daha önce glokom teşhisi konan hastaya ayrıca antiglokomatöz tedavi uygulanmıştır.

Anahtar Kelimeler:

Agomelatine, Angle closure glaucoma

Acute angle closure glaucoma induced by selective serotonin reuptake inhibitor, and reversed by agomelatine

Agomelatine, a MT1 (Melatonin) and MT2 receptor agonist and 5-HT2C (5-Hidroksitriptamin) antagonist, is an antidepressant agent used in the treatment of major depressive disorders. Intraocular pressure lowering effect of melatonin and its analogues have been demonstrated in a few experimental studies. In the present case report, we have documented the reversal of angle closure glaucoma by oral agomelatine in a patient with major depressive disorder under selective serotonine reuptake inhibitor treatment. The patient, who had previously been diagnosed with glaucoma, was also receiving antiglaucomatous treatment.

PDF

___

1. Zhang X, Liu Y, Wang W, Chen S, Li F, Huang W et al. Why does acute primary angle closure happen? Potential risk factors for acute primary angle closure. Surv Ophthalmol. 2017;62:635-47.
2. 2.Ahmad S. Fluoxetine and glaucoma. DICP. 1991;25:436.
3. de Guzman MH, Thiagalingam S, Ong PY, Goldberg I. Bilateral acute angleclosure caused by supraciliary effusions associated with venlafaxine intake. Med. J Aust. 2005;182:121-3.
4. Alarma-Estrany P, Pintor J. Melatonin receptors in theeye: location, second messengers and role in ocular physiology. Pharmacol Ther. 2007;113:507– 22.
5. Crooke A, Huete-Toral F, Martınez-Aguila A, Martın-Gil A, Pintor J. Melatonin and its analogue 5- methoxycarbonyl amino-N-acetyl tryptamine potentiate adrenergic receptor-mediated ocular hypotensive effects in rabbits: significance for combination therapy in glaucoma. J Pharmacol Exp Ther. 2013;346:138–45.
6. European Glaucoma Society. Primitive angle closure. In: Guide for glaucoma 2nd edition. Dogma, Savona, Italy. 2003;2-13.
7. Osborne NN, Tobin AB. Serotonin accumulating cells in the iris-ciliary body and cornea of various species. Exp Eye Res. 1987;44:731-45.
8. Costagliola C, Parmeggiani F, Semeraro F, Sebastiani A. Selective serotonin reuptake inhibitors: a review of its effects on intraocular pressure. Curr Neuropharmacol. 2008;6:293-310.
9. Lachkar Y, Bouassida W. Drug-induced acute angle closure glaucoma. Curr Opin Ophthalmol. 2007;18:129-33.
10. Croos R, Thirumalai S, Hassan S, Davis Jda R. Citalopram associated with acute angle-closure glaucoma: case report. BMC Ophthalmol. 2005;5:23.
11. Ismail SA, Mowafi HA. Melatonin provides anxiolysis, enhances analgesia, decreases intraocular pressure, and promotes better operating conditions during cataract surgery under topical anesthesia. Anesth Analg. 2009;108:1146–1151.
12. Serle JB, Wang RF, Peterson WM, Plourde R, Yerxa BR. Effect of 5-MCA-NAT, a putative melatonin MT3 receptor agonist, on intraocular pressure in glaucomatous monkey eyes. J Glaucoma. 2004;13:385–8.
13. Conway S, Canning SJ, Howell HE, Mowat ES, Barrett P, Drew JE et al. Characterisation of human melatonin MT(1) and MT(2) receptors by CREluciferase reporter assay. Eur J Pharmacol. 2000;390:15–24.
14. 14.Martinez-Aguila A, Pintor J. Melatonin analogue agomelatine reduces rabbit’s intraocular pressure in normotensive and hypertensive conditions. Eur J Pharmacol. 2013;701:213–7.
15. Alarma-Estrany P, Crooke A, Mediero A, Pelaez T, Pintor J. Sympathetic nervous system modulates the ocular hypo-tensive action of MT2-melatonin receptors in normotensive rabbits. J Pineal Res. 2008;45:468–75.